Description
Tesamorelin 20 mg — GHRH Analog for Visceral Fat & Endocrine Research
Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analog designed to stimulate endogenous growth hormone (GH) secretion via pituitary GHRH receptors. In preclinical and clinical research, Tesamorelin has been studied for its effects on visceral adipose tissue (VAT), body composition, and metabolic/endocrine markers, particularly in settings of altered fat distribution.
What It Is
Class: GHRH (growth hormone–releasing hormone) analog Concept: Mimics native GHRH signaling to increase pulsatile GH release and secondarily influence IGF-1 and downstream metabolic endpoints. Format: Research-grade synthetic peptide supplied as a lyophilized powder.
Proposed Mechanisms (Preclinical)
GHRH–Pituitary Axis
Activates GHRH receptors on pituitary somatotroph cells. Engages cAMP/PKA signaling pathways linked to GH synthesis and secretion. Supports pulsatile GH release rather than continuous exogenous GH exposure.
Downstream Body-Composition Effects
Research explores changes in visceral adipose tissue, trunk fat, and overall body-composition indices. Model-dependent effects on IGF-1 levels, lipid profiles, and metabolic markers. Interest in differentiation between subcutaneous vs. visceral fat responses.
Selected Research Highlights
Visceral Fat Models: Tesamorelin has been studied for reductions in visceral adipose tissue and changes in trunk/abdominal fat distribution in select clinical populations. Growth Hormone Axis: Investigations report increases in GH/IGF-1 parameters with GHRH analog exposure, with associated changes in body composition and metabolic readouts. Metabolic & Cardiovascular Markers: Research includes effects on lipids, glucose control, and cardiovascular risk markers in model systems. Aging & Endocrine Research: GHRH analogs are of interest in broader studies of endocrine aging, anabolic–catabolic balance, and tissue repair.
Chemical & Handling Information
Type: Synthetic growth hormone–releasing hormone analog Backbone: Modified GHRH(1–44)–type sequence with stabilizing substitutions (exact sequence per specification/lot) Appearance: White to off-white lyophilized powder
Specifications
Peptide: Tesamorelin Amount: 20 mg per vial Form: Lyophilized powder Purity: ≥99% (HPLC); COA per lot available Packaging: Sealed vials suitable for standard laboratory handling
Storage & Stability
Store lyophilized vials in a cool, dry place, protected from light. Refrigeration or freezing of the lyophilized peptide is recommended for extended stability, according to laboratory SOPs. After reconstitution, store at 2–8 °C for short-term use. For long-term storage, aliquot and freeze at −20 °C or below; avoid repeated freeze–thaw cycles.